219 related articles for article (PubMed ID: 37978195)
21. Benchmarking Bioinformatics Pipelines in Data-Independent Acquisition Mass Spectrometry for Immunopeptidomics.
Shahbazy M; Ramarathinam SH; Illing PT; Jappe EC; Faridi P; Croft NP; Purcell AW
Mol Cell Proteomics; 2023 Apr; 22(4):100515. PubMed ID: 36796644
[TBL] [Abstract][Full Text] [Related]
22. Mass spectrometric analysis of the HLA class I peptidome of melanoma cell lines as a promising tool for the identification of putative tumor-associated HLA epitopes.
Gloger A; Ritz D; Fugmann T; Neri D
Cancer Immunol Immunother; 2016 Nov; 65(11):1377-1393. PubMed ID: 27600516
[TBL] [Abstract][Full Text] [Related]
23. Optimized Liquid and Gas Phase Fractionation Increases HLA-Peptidome Coverage for Primary Cell and Tissue Samples.
Klaeger S; Apffel A; Clauser KR; Sarkizova S; Oliveira G; Rachimi S; Le PM; Tarren A; Chea V; Abelin JG; Braun DA; Ott PA; Keshishian H; Hacohen N; Keskin DB; Wu CJ; Carr SA
Mol Cell Proteomics; 2021; 20():100133. PubMed ID: 34391888
[TBL] [Abstract][Full Text] [Related]
24. Immunopeptidomics-Guided Warehouse Design for Peptide-Based Immunotherapy in Chronic Lymphocytic Leukemia.
Nelde A; Maringer Y; Bilich T; Salih HR; Roerden M; Heitmann JS; Marcu A; Bauer J; Neidert MC; Denzlinger C; Illerhaus G; Aulitzky WE; Rammensee HG; Walz JS
Front Immunol; 2021; 12():705974. PubMed ID: 34305947
[TBL] [Abstract][Full Text] [Related]
25. Guidance Document: Validation of a High-Performance Liquid Chromatography-Tandem Mass Spectrometry Immunopeptidomics Assay for the Identification of HLA Class I Ligands Suitable for Pharmaceutical Therapies.
Ghosh M; Gauger M; Marcu A; Nelde A; Denk M; Schuster H; Rammensee HG; Stevanović S
Mol Cell Proteomics; 2020 Mar; 19(3):432-443. PubMed ID: 31937595
[TBL] [Abstract][Full Text] [Related]
26. Sensitive, high-throughput HLA-I and HLA-II immunopeptidomics using parallel accumulation-serial fragmentation mass spectrometry.
Phulphagar KM; Ctortecka C; Vaca Jacome AS; Klaeger S; Verzani EK; Hernandez GM; Udeshi N; Clauser K; Abelin J; Carr SA
bioRxiv; 2023 Mar; ():. PubMed ID: 36993564
[TBL] [Abstract][Full Text] [Related]
27. Deciphering Human Leukocyte Antigen Susceptibility Maps From Immunopeptidomics Characterization in Oncology and Infections.
Juanes-Velasco P; Landeira-Viñuela A; Acebes-Fernandez V; Hernández ÁP; Garcia-Vaquero ML; Arias-Hidalgo C; Bareke H; Montalvillo E; Gongora R; Fuentes M
Front Cell Infect Microbiol; 2021; 11():642583. PubMed ID: 34123866
[TBL] [Abstract][Full Text] [Related]
28. Upstream open reading frames regulate translation of cancer-associated transcripts and encode HLA-presented immunogenic tumor antigens.
Nelde A; Flötotto L; Jürgens L; Szymik L; Hubert E; Bauer J; Schliemann C; Kessler T; Lenz G; Rammensee HG; Walz JS; Wethmar K
Cell Mol Life Sci; 2022 Mar; 79(3):171. PubMed ID: 35239002
[TBL] [Abstract][Full Text] [Related]
29. Differential ion mobility mass spectrometry in immunopeptidomics identifies neoantigens carrying colorectal cancer driver mutations.
Minegishi Y; Kiyotani K; Nemoto K; Inoue Y; Haga Y; Fujii R; Saichi N; Nagayama S; Ueda K
Commun Biol; 2022 Aug; 5(1):831. PubMed ID: 35982173
[TBL] [Abstract][Full Text] [Related]
30. Proteogenomic Analysis Unveils the HLA Class I-Presented Immunopeptidome in Melanoma and EGFR-Mutant Lung Adenocarcinoma.
Qi YA; Maity TK; Cultraro CM; Misra V; Zhang X; Ade C; Gao S; Milewski D; Nguyen KD; Ebrahimabadi MH; Hanada KI; Khan J; Sahinalp C; Yang JC; Guha U
Mol Cell Proteomics; 2021; 20():100136. PubMed ID: 34391887
[TBL] [Abstract][Full Text] [Related]
31. Deep learning boosts sensitivity of mass spectrometry-based immunopeptidomics.
Wilhelm M; Zolg DP; Graber M; Gessulat S; Schmidt T; Schnatbaum K; Schwencke-Westphal C; Seifert P; de Andrade Krätzig N; Zerweck J; Knaute T; Bräunlein E; Samaras P; Lautenbacher L; Klaeger S; Wenschuh H; Rad R; Delanghe B; Huhmer A; Carr SA; Clauser KR; Krackhardt AM; Reimer U; Kuster B
Nat Commun; 2021 Jun; 12(1):3346. PubMed ID: 34099720
[TBL] [Abstract][Full Text] [Related]
32. Mass Spectrometry-Based Immunopeptidomics of Peptides Presented on Human Leukocyte Antigen Proteins.
ElAbd H; Franke A
Methods Mol Biol; 2024; 2758():425-443. PubMed ID: 38549028
[TBL] [Abstract][Full Text] [Related]
33. Accurate MHC Motif Deconvolution of Immunopeptidomics Data Reveals a Significant Contribution of DRB3, 4 and 5 to the Total DR Immunopeptidome.
Kaabinejadian S; Barra C; Alvarez B; Yari H; Hildebrand WH; Nielsen M
Front Immunol; 2022; 13():835454. PubMed ID: 35154160
[TBL] [Abstract][Full Text] [Related]
34. Sensitive Immunopeptidomics by Leveraging Available Large-Scale Multi-HLA Spectral Libraries, Data-Independent Acquisition, and MS/MS Prediction.
Pak H; Michaux J; Huber F; Chong C; Stevenson BJ; Müller M; Coukos G; Bassani-Sternberg M
Mol Cell Proteomics; 2021; 20():100080. PubMed ID: 33845167
[TBL] [Abstract][Full Text] [Related]
35. IFNγ Modulates the Immunopeptidome of Triple Negative Breast Cancer Cells by Enhancing and Diversifying Antigen Processing and Presentation.
Goncalves G; Mullan KA; Duscharla D; Ayala R; Croft NP; Faridi P; Purcell AW
Front Immunol; 2021; 12():645770. PubMed ID: 33968037
[TBL] [Abstract][Full Text] [Related]
36. Data-Independent Acquisition of HLA Class I Peptidomes on the Q Exactive Mass Spectrometer Platform.
Ritz D; Kinzi J; Neri D; Fugmann T
Proteomics; 2017 Oct; 17(19):. PubMed ID: 28834231
[TBL] [Abstract][Full Text] [Related]
37. Identification and validation of expressed HLA-binding breast cancer neoepitopes for potential use in individualized cancer therapy.
Reimann H; Nguyen A; Sanborn JZ; Vaske CJ; Benz SC; Niazi K; Rabizadeh S; Spilman P; Mackensen A; Ruebner M; Hein A; Beckmann MW; van der Meijden ED; Bausenwein J; Kretschmann S; Griffioen M; Schlom J; Gulley JL; Lee KL; Hamilton DH; Soon-Shiong P; Fasching PA; Kremer AN
J Immunother Cancer; 2021 Jun; 9(6):. PubMed ID: 34172517
[TBL] [Abstract][Full Text] [Related]
38. Immunopeptidomics-based identification of naturally presented non-canonical circRNA-derived peptides.
Ferreira HJ; Stevenson BJ; Pak H; Yu F; Almeida Oliveira J; Huber F; Taillandier-Coindard M; Michaux J; Ricart-Altimiras E; Kraemer AI; Kandalaft LE; Speiser DE; Nesvizhskii AI; Müller M; Bassani-Sternberg M
Nat Commun; 2024 Mar; 15(1):2357. PubMed ID: 38490980
[TBL] [Abstract][Full Text] [Related]
39. PeptiCHIP: A Microfluidic Platform for Tumor Antigen Landscape Identification.
Feola S; Haapala M; Peltonen K; Capasso C; Martins B; Antignani G; Federico A; Pietiäinen V; Chiaro J; Feodoroff M; Russo S; Rannikko A; Fusciello M; Koskela S; Partanen J; Hamdan F; Tähkä SM; Ylösmäki E; Greco D; Grönholm M; Kekarainen T; Eshaghi M; Gurvich OL; Ylä-Herttuala S; M Branca RM; Lehtiö J; Sikanen TM; Cerullo V
ACS Nano; 2021 Oct; 15(10):15992-16010. PubMed ID: 34605646
[TBL] [Abstract][Full Text] [Related]
40. Antigen discovery for the development of cancer immunotherapy.
Ahn R; Cui Y; White FM
Semin Immunol; 2023 Mar; 66():101733. PubMed ID: 36841147
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
